anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The primary research objective is to evaluate neuroimaging predictors of a positive response to CIMT in children with hemiplegic CP secondary to a middle cerebral artery territory stroke (MCA). A focus on the MCA territory is chosen as (1) it targets children with significant hand impairment who have the potential to benefit from CIMT, (2) is the most common neuropathological subtype, and (3) allows for enhanced homogeneity for the matching of case and comparison groups. The primary research question is: In children aged 7 to 16 years with hemiplegic CP secondary to an MCA stroke, are there neuroimaging predictors of a positive response to CIMT, a positive response being defined by an improvement in the Assisting Hands Assessment (AHA) one month after CIMT?

Neuroimaging predictor variables include laterality index (LI) of the primary M1 and S1 areas on fMRI, IHI evaluated by resting state fMRI, dissociation of the M1 and S1 for the hemiplegic hand measured by fMRI, size and vascular distribution of the MCA lesion with T2 weighted MRI, and white matter tract abnormality with Diffusion Tensor Imaging (DTI). We hypothesize that a negative LI, a non-dissociated M1 and S1, low IHI, small size of infarction, and large size of the contralateral corticospinal tract will predict a positive response to constraint. An evaluation of the neuroimaging predictor variables on the persistence of a positive response to CIMT at 6 months as measured by the AHA will also be explored. A secondary objective will evaluate change in the neuroimaging variables from baseline to one month post CIMT by comparing children in the case group who have received CIMT and a comparison group who are matched on baseline QUEST scores.
The invention belongs to the field of traditional Chinese medicine, and specifically relates to an external medicine used for treating parotitis. The medicine is prepared by using traditional Chinese medicine materials. The medicine is characterized in that: 3-5 parts of Chinese goldthread rhizome by weight, 3-5 parts of indigowoad leaf by weight, 3-5 parts of snakegourd root by weight, 3-5 parts of begonia edulis by weight, 1-2 parts of prepared centipede by weight, 1-2 parts of flatspine pricklyash by weight, and 0.5-1 parts of borneol by weight are grinded into powder; the powder is blended with aconitum brachypodum diels medicinal liquor, such that a paste is obtained; the paste is filled, and a finished product is obtained. In the aconitum brachypodum diels medicinal liquor, a weight ratio of aconitum brachypodum diels to ethanol is 1:1-1.5, and a soaking period is larger than 3 months. The prepared centipede is prepared through steps that: centipede is wrapped by using green duck egg shells, and is baked, such that dry powder is obtained. The external medicine liquid provided by the invention is advantaged in good curative effect, convenient application, and no toxic or side effect.
Prepn. of a stabilised pharmaceutical prepn. by mixing (a) water, (b) a cpd. with antitumour activity and a glucan skeleton, (c) as a prim., water-soluble solubilising agent: a dextran, hydroxyethyl starch, carboxymethylcellulose or polyethyleneglycol in sufficient quantity to increase the solubility of (b); and (c) a sec. water-soluble solubilising agent at 0-10g/dl, consisting of a pentose, hexose or 5-6C sugar alcohol. The solns. have antitumor activity and may be administered intravenously. Addn. of the solubilising agents increases the solubility of active component to give solns. stable upon storage without pptn. and without losing activity.
If significant diarrhea occurs during therapy, this antibacterial drug should be discontinued (See BOXED WARNING).

Administer CLEOCIN HCl Capsules with a full glass of water (6 to 8 ounces, approximately 200 to 250 mL) and at least 30 minutes before lying down to reduce the potential for esophageal irritation (See ADVERSE REACTIONS).

Adults: Serious infections – 150 to 300 mg every 6 hours. More severe infections – 300 to 450 mg every 6 hours.

Pediatric Patients (who are able to swallow capsules): Serious infections – 8 to 16 mg/kg/day (4 to 8 mg/lb/day) divided into three or four equal doses. More severe infections – 16 to 20 mg/kg/day (8 to 10 mg/lb/day) divided into three or four equal doses. Clindamycin should be dosed based on total body weight regardless of obesity.

CLEOCIN HCl Capsules are not suitable for pediatric patients who are unable to swallow them whole. The capsules do not provide exact mg/kg doses therefore it may be necessary to use the clindamycin palmitate oral solution in some cases.

Serious infections due to anaerobic bacteria are usually treated with CLEOCIN PHOSPHATE® Sterile Solution. However, in clinically appropriate circumstances, the physician may elect to initiate treatment or continue treatment with CLEOCIN HCl Capsules.

In cases of β-hemolytic streptococcal infections, treatment should continue for at least 10 days.
Lung cancer remains the leading cause of cancer-related deaths, with cigarette smoking being the most critical factor, linked to nearly 90% of lung cancer cases. NNK, a highly carcinogenic nitrosamine found in tobacco, is implicated in the lung cancer-causing effects of cigarette smoke. Although NNK is known to mutate or activate certain oncogenes, its potential interaction with p27 in modulating these carcinogenic effects is currently unexplored. Recent studies have identified specific downregulation of p27 in human squamous cell carcinoma, in contrast to adenocarcinoma. Additionally, exposure to NNK significantly suppresses p27 expression in human bronchial epithelial cells. Subsequent studies indicates that the downregulation of p27 is pivotal in NNK-induced cell transformation. Mechanistic investigations have shown that reduced p27 expression leads to increased level of ITCH, which facilitates the degradation of Jun B protein. This degradation in turn, augments miR-494 expression and its direct regulation of JAK1 mRNA stability and protein expression, ultimately activating STAT3 and driving cell transformation. In summary, our findings reveal that: (1) the downregulation of p27 increases Jun B expression by upregulating Jun B E3 ligase ITCH, which then boosts miR-494 transcription; (2) Elevated miR-494 directly binds to 3'-UTR of JAK1 mRNA, enhancing its stability and protein expression; and (3) The JAK1/STAT3 pathway is a downstream effector of p27, mediating the oncogenic effect of NNK in lung cancer. These findings provide significant insight into understanding the participation of mechanisms underlying p27 inhibition of NNK induced lung squamous cell carcinogenic effect.
The invention discloses a kind of for antineoplastic siRNA and application thereof, does this siRNA comprise the one be selected from following nucleotide sequences: as SEQ? ID? NO.7-12 or SEQ? ID? RNA sequence shown in NO.15-126, with SEQ? ID? NO.7-12 or SEQ? ID? the RNA sequence that NO.15-126 limits has more than 90% homology, and has the RNA sequence of identical function.SiRNA of the present invention can suppress human FAK genetic expression, can be applicable to preparing in anti-tumor drug, for the exploitation for the treatment of or anti-curing oncoma (as liver cancer) new drug provides new approach.
Human Cytomegalovirus(CMV), a kind of β-hepersvirus, which is a common opportunistic pathogen. The ubiquity of CMV infection in human beings had been verified; and the CMV-IgG seropositive rate is 97% among healthy population, most of them are at the state of latent infection. When immunosuppressed, such as for renal transplant recipients, the incidence of CMV infection and disease increase obviously. The posttransplant CMV infection would induce allgraft rejection, impact on allgraft and recipients survival, as well as contribute to the serious complications.Many studies show that giving effective antivirus drugs after transplantation is benifit to recipients.

Nowadays,the strategy of intravenous GCV GCV 5mg/kg daily or oral GCV 1g 3 times daily, which is the recommended treatment for CMV disease posttransplantation.Resent date show that VGC is an oral prodrug of GCV. When VGC is absorbed in the intestinal wall and liver, it is rapidly metabolized to ganciclovir. As a contemporary study, IV GCV 5mg/kg/day will approach to a similar area under the curve to VGC 900mg daily. The bioavailability of ganciglovir from valganciclovir is 10 times of GCV by oral. For recipients, oral therapy is more safety and convinient, so that it will reduce frequent hospitalizations. As many researches, it is indicated that oral VGC 450mg daily can also reduce the adverse events resulting from posttransplant CMV infection, there is no significantly statistic differences when compared with oral VGC 900mg daily. Simultaneously, lower dose could decrease the risk of leukopenia and ease the burden for recipients.

This study is a single-center, prospective, observational, corhort study. According to the inclusion and exclusion criteria, the investigators will recruit 450 patients. And every one will be followed up for at least 12 months unless death or graft loss, the specific duration is at baseline, weekly within the first 3 months posttransplantation, month 4, month 5, month 6, month 9, and month 12. Recipients will be followed for CMV-DNA, CMV-pp65, CMV antigenemia, blood routine test, urinalysis, liver function, renal fuction and the chest X-ray films. Inverstigators should collect the date of recipient as below: general conditions, such as age, sex, weight and so on; primary reason for transplant; donor/recipient CMV serostatus; biopsy-prove acute rejection; opportunistic infections; NODAT; etc. And Chi-square or Fisher's exact test will be used as appropriate to compare categorical variables, and it is considered as statistically significant when the 2-sided P-value\<0.05. Definitively, conclusion will be come out to verify the safety and availability of our protocol.
PURPOSE:To provide an aerosol compsn. in which air pollution problem is controlled and which has excellent spraying stability and drying characteristics after coating, by incorporating carbon dioxide gas into a stock soln. composed of 1,1,2-trichlorotrifluoroethane contg. a reagent to be coated on the human body. CONSTITUTION:A reagent to be coated on the human body is used which protects coated parts of the human body from sweat, odor, etc., that is, which is effective in hidroschesis, deodrizing, softening, etc., or effective in beauty when coated on the skin, hair, etc. The reagent is dissolved in a solvent composed of 1,1,2-trichlorotrifluoroethane alone to form an aerosol stock soln. A propellant composed of carbon dioxide gas alone or a mixture of carbon dioxide gas and dimethyl ether or LP gas, is blended with the above stock soln. to obtain an aerosol compsn. Although carbon dioxide gas as a propellant is gas, it has a good effect on dividing liquids just in front of the spraying port of an aerosol container. Fine atomization is conducted as in the use of conventional fluorine propellant.
This study was initially designed to explore the safety and efficacy of short-course HIPEC in terms of median progression-free survival (PFS) as the primary outcome. However, due to slow accrual, the design was subsequently amended to explore the primary outcome measure of PD9 (i.e.: proportion of patients with disease progression or death occurring within 9 months of IDS plus HIPEC). The hypothesis was the short-course HIPEC could decrease PD9 with low rates of morbidity and mortality. In these settings, we explore a comprehensive treatment approach involving fast-track advanced cytoreductive surgery (CRS) plus short-course HIPEC at the time of IDS following NACT for high tumor burden patients with stage III-IV ovarian cancer. Advanced CRS was performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity, and fast-track recovery strategies were also applied to improve patient outcomes. HIPEC was performed according to the closed-abdomen technique using CDDP (25 mg/L of perfusate/m2, total limit of 240mg) or CDDP plus Doxorubicin (15mg/L) for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 4L to 6L) was circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min. Systemic chemotherapy included the standard combination of carboplatin and paclitaxel as neo-adjuvant plus adjuvant regimens.
Patients undergo IGART using ABC 5 days a week for 7 weeks, for a total of 33 fractions with SIVAB during fractions 26-33. Patients also receive paclitaxel IV over 1 hour and carboplatin IV over 30 minutes once a week for 6 weeks.
PURPOSE: A composition for cooling skin, containing alcohols and phenol is provided to be easily cooled and to maintain low temperatures. CONSTITUTION: A composition for cooling skin contains a solution containing water, alcohols, and phenol. The solution contains 0.1-15 wt% of alcohols, 0.001-0.5 wt% of phenol, and remaining amount of water. The alcohols are methyl alcohol or ethyl alcohol. A skin cooling sensor is a container in which the solution is supported. The container has a head part which comes in contact with skin and a body part which is easy to be gripped. [Reference numerals] (AA) Skin temperature [°C]; (BB) Water; (CC) Mixture; (DD) Time [min]
PROBLEM TO BE SOLVED: To obtain the subject inhibitor having high inhibiting actions on cancer metastasis and reduced in adverse effects by using L-ascorbic acid tetra-fatty acid ester as an active ingredient. SOLUTION: This inhibitor contains L-ascorbic acid tetra-fatty acid ester (e.g. L-ascorbyl tetraisopalmitate which is a tetraester of L-ascorbic acid with a fatty acid (e.g. 2-hexyldecanoic acid, undecylenic acid or palmitoleic acid) as an active ingredient. The active ingredient is preferably included in an amount of 0.001-100 wt.% in a preparation or a composition. The daily dose of the inhibitor for an adult based on 1 kg body weight is preferably 0.001-8,500 mg expressed in terms of the amount of the active ingredient in the case of oral administration, suppository administration, a preparation for external use, etc., and preferably 0.025-200 mg expressed in terms of the amount of the active ingredient in the case of intravenous injection and drip infusion administered in one to divided several portions.  The inhibitor is useful for malignant melanoma, cancer of digestive organs, esophageal carcinoma, Kaposi's sarcoma, etc.
A carcinogenicity study was not conducted with belatacept. However, a murine carcinogenicity study was conducted with abatacept (a more active analog in rodents) to determine the carcinogenic potential of CD28 blockade. Weekly subcutaneous injections of 20, 65, or 200 mg per kg of abatacept were associated with increases in the incidence of malignant lymphomas (all doses) and mammary gland tumors (intermediate- and high-dose in females) at clinically relevant exposures. The mice in this study were infected with endogenous murine leukemia and mouse mammary tumor viruses which are associated with an increased incidence of lymphomas and mammary gland tumors, respectively, in immunosuppressed mice. Although the precise relevance of these findings to the clinical use of NULOJIX is unknown, cases of PTLD (a premalignant or malignant proliferation of B lymphocytes) were reported in clinical trials.

Genotoxicity testing is not required for protein therapeutics; therefore, no genotoxicity studies were conducted with belatacept.

Belatacept had no adverse effects on male or female fertility in rats at doses up to 200 mg per kg daily (25 times the MRHD exposure).
FIELD: microbiological industry. SUBSTANCE: method involves grinding, homogenizing and centrifuging the source material (thymus gland). Supernatant liquid is then subjected to dialysis. After extracting the required fraction of substances, the dialysate is dried by sublimation. Dialysate is freezed directly in sublimation chamber to minus 40-44 C at the rate of 12 C/h and held at this temperature for 3-5 h. Drying is carried out in two stages by alternating material heating and holding periods. At the first stage the material is heated at the rate of 5 C/h and held at 8-12 C for 5-7 h while at the second stage it is heated at the rate of 3 C/h and held at a material temperature of 28-32 C. Activity of end product is 47 ± 2%. EFFECT: higher specific activity of end product achieved by mild drying conditions and a speedier method.
Although a few instances of cardiac dysfunction have been reported following use of recommended doses of cyclophosphamide, no causal relationship has been established. Acute cardiac toxicity has been reported with doses as low as 2.4 g/m2 to as high as 26 g/m2, usually as a portion of an intensive antineoplastic multi-drug regimen or in conjunction with transplantation procedures. In a few instances with high doses of cyclophosphamide, severe, and sometimes fatal, congestive heart failure has occurred after the first cyclophosphamide dose. Histopathologic examination has primarily shown hemorrhagic myocarditis. Hemopericardium has occurred secondary to hemorrhagic myocarditis and myocardial necrosis. Pericarditis has been reported independent of any hemopericardium. 

No residual cardiac abnormalities, as evidenced by electrocardiogram or echocardiogram appear to be present in patients surviving episodes of apparent cardiac toxicity associated with high doses of cyclophosphamide. 

Cyclophosphamide has been reported to potentiate doxorubicin-induced cardiotoxicity.
This disclosure is directed to compositions comprised of retinaldehyde, one or more skin conditioning agents, and, optionally, one or more additional retinoids. This disclosure is directed. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Embodiments are also directed to compositions comprised of retinaldehyde, one or more peptides, one or more skin conditioning agents, one or more calcium containing agents, and, optionally, one or more additional retinoids. Additional embodiments disclose methods for treating the skin wherein a characteristic of the skin is improved, the characteristics include firmness, elasticity, fine lines and wrinkles, skin texture, dullness, dyschromia, skin tone, reduction or elimination of acne, and any combination thereof. This disclosure is also directed to kits used for treating the skin with the compositions described herein.
Laser thermotherapy can increase the stiffness of vaginal wall. It has been reported that vaginal laser therapy can be used to treat stress urinary incontinence. However, factor affecting treatment efficacy of vaginal laser therapy remains unknown. Thus the main aim of this study is to elucidate factors affecting treatment efficacy of vaginal laser therapy. Besides, the durability of vaginal laser therapy will be assessed. The above knowledge should be helpful for clinical decision making.
This is an observational, single-cohort, prospective study of systemic chemotherapy after CRS/HIPEC. Subjects will be given twelve months of 5-FU or capecitabine with bevacizumab starting 4-16 weeks after surgery. CTRI Biostatistics Core personnel will assist in conducting analyses using the latest version of R (R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/).

No therapy is included in this study. Subjects have already previously undergone surgery for their cancer. This study will observe the outcomes of the postoperative chemotherapy treatment the doctor chooses to treat the subject's cancer.
High Frequency Group: In this group the TENS will be adjusted with frequency of 150Hz, pulse duration of 200 microseconds. The stimulation time will be 30 minutes and the intensity will be constantly adjusted in order to keep as high as possible within the tolerance threshold of the patient.
<P>PROBLEM TO BE SOLVED: To develop a new material for preventing hands/feet and/or face dropsy symptoms and dropsy feeling which are developed spontaneously in daily life, and to provide a dropsy-preventive agent and an oral composition each using the above new material.  <P>SOLUTION: The dropsy-preventive agent comprises, as an active ingredient, a plant belonging to the genus Astilbe such as Astilbe thunbergii (SIEB. et ZUCC.) Miq., more preferably its extract obtained by extraction of the plant with water and/or a hydrophilic organic solvent. The oral composition containing the above dropsy-preventive agent is also provided. Besides, a method for preventing dropsy characterized by comprising orally administering the plant or its extract is provided.  <P>COPYRIGHT: (C)2010,JPO&INPIT
Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g. AST, ALT, alkaline phosphatase and bilirubin).

The concomitant use of alcohol or other central nervous system depressants may have an additive effect.

Usage in Pregnancy: The safe use of Chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.
Abstract For admixing a gaseous substance, especially an odoriferous substance, to a gas stream the gaseous substance is fed by means of a carrier gas (23) via a line (10) to a mixing chamber (1). The line contains at least one capillary (19), which is arranged in an advancing device (9) with two defined positions. In one position the capillary extends through an opening (6), provided with shut-off means (7), into the mixing chamber. In the second position it opens outside of the mixing chamber in a suction removal space (25) surrounding the mixing chamber. The carrier gas is preferably flowing continuously. Suction removal means (26) are provided which suck off the carrier gas together with the gaseous substance from the capillary when the latter is in the position where itopens in the suction removal space.
The patients randomized to this arm will recieve one placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.